EU Seeks Feedback on Extending Biocide Substance Review Period

Dr Steven Brennan
Dr Steven Brennan
2 min read·AI-drafted, expert reviewed
Disinfectants sitting on a table

The European Commission has announced a proposed extension to the review period for existing active substances in biocidal products, a move that underscores the complexity and importance of ensuring the safety and efficacy of these substances in the EU market.

Under the current EU regulations, a thorough examination of active substances used in biocidal products is mandatory. However, the initial deadline of December 31, 2024, for this review is proposed to be extended, acknowledging the challenges and delays encountered in the process.

The Need for Extension

The extension stems from the realisation that the review cannot be completed within the original timeframe. This is partly due to the intricate nature of the assessments and the need for additional data and analysis, especially in light of new scientific criteria for determining endocrine-disrupting properties.

In line with the EU's commitment to transparency and stakeholder engagement, the Commission has opened a feedback period from 23 November to 21 December 2023. Stakeholders are encouraged to review the draft act and provide their insights. This feedback will be instrumental in refining the initiative, with all submissions being publicly available on the EU's portal.

Looking Ahead: Commission Adoption and Beyond

The Commission plans to adopt the final regulation in the first quarter of 2024. This extension to December 31, 2030, is seen as a pragmatic step, balancing the need for thorough review against the practicalities of regulatory processes.

Stay informed on the latest developments in biocidal products regulation, including this extension, by subscribing to Signal. Get timely updates and insights directly to your inbox.

Related Articles

Join 3,500+ professionals staying ahead

Subscribe to Foresight Weekly and get the latest insights on regulatory changes affecting chemical compliance.

Free forever. Unsubscribe anytime.

Read by professionals at

Boeing
AstraZeneca
Siemens
PepsiCo
SpaceX